Kenneth C Frazier

Director

Kenneth C Frazier (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Eikon Therapeutics, Inc. (EIKN). Across 1 priced purchase filing, the average 21-session return was -15.7% from execution and -2.0% from disclosure (delay-adjusted; derived). The largest single filing was $2.0M of EIKN (111,111 sh × $18.00, as filed), executed Feb 4.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

-15.7%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

-2.0%

same 1 filings, from disclosure

Filings, ttm

1 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$2.0M

shares × price, as filed

Last traded

Feb 4

Filed Feb 6

Median ADV $4.4M across their filed names

Open performance→

Volume by month

Buys $2.0M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names

EIKN

Eikon Therapeutics, Inc. EIKN · 1 buy · 0 sells 1 filing

Recent filings

EIKNPURCHASE Eikon Therapeutics, Inc. View filing → $2.0M
111,111 sh × $18.00
Exec Feb 4
Filed Feb 6 · 6:33 PM ET